Farnum Rhonda 4

What Happened Rhonda Farnum, Senior Vice President, Communications & Medical Affairs at Theravance Biopharma (TBPH), was granted 18,750 shares on 2026-04-01. The filing reports the acquisition price as $0.00, so the transaction value is listed as $0 (award/grant).

Key Details

• Transaction date: 2026-04-01
• Transaction type/code: Award/Grant (A)
• Shares granted: 18,750
• Reported price per share: $0.00; reported total value: $0
• Shares owned after transaction: not specified in the provided filing summary
• No footnotes, 10b5-1, or tax-withholding details were included in the provided information
• Filing timeliness: no late-filing flag indicated in the provided summary

Context Grants and awards are typically part of executive compensation (e.g., restricted stock or RSUs) and do not represent an open-market purchase or sale. Such awards don’t by themselves indicate the insider’s buying/selling intent; they reflect company compensation decisions.